News
Bloom Science Completes Successful Pre-IND Meeting with the FDA for BL-001 Clinical Trial to Treat Dravet Syndrome
SAN DIEGO, Calif., January 4, 2023 -- Bloom Science, Inc., a clinical-stage biotechnology company developing novel medicines for neurological diseases and conditions, successfully completed a...
Bloom Science to Present Live at Biotech Showcase 2023
SAN DIEGO, Calif., December 17, 2022 -- Bloom Science, Inc. founder & CEO Christopher Reyes, PhD presents live at Biotech Showcase™ 2023 on Tuesday January 10 at 2:45 p.m. PT. Biotech Showcase,...
Harnessing the Gut–Immune–Brain Axis to Treat Disease
How a 100-year-old study spawned a novel class of multifunctional neurological treatments. Read the latest on Bloom Science's epilepsy and ALS lead programs and how a 100-year-old study spawned a...
Bloom Science Raises USD $12 Million in Series A Financing
Bloom Science is developing novel engineered and rationally selected microbiome-based treatments for neurological and inflammatory diseases with initial programs in Drug Resistant Epilepsy and...
The ALS Association Awards Bloom Science to Develop Novel Gut Microbiota-based Therapies for Amyotrophic Lateral Sclerosis
Bloom Science, a biopharmaceutical company focused on the discovery and development of medicines tailored for individual patients living with neurological diseases, has received a $500,000 grant...
Bloom Science Launches to Develop Neuroprotective Epilepsy Treatments in Orphan Indications with Exclusive Technology License from UCLA
Study published in Cell demonstrates causal link between seizure susceptibility and the microbiome, identifies gut bacteria that confer anti-seizure effects Bloom Science, a biotechnology company...